Bio-Manguinhos: PARTNERSHIP FOR THE WORLD PUBLIC HEALTH

The Immunobiological Technology Institute - Bio-Manguinhos is the biggest and most modern federal laboratory for R&D and production of immunobiologics and IVD reagents in Brazil – the South America’s leading economy, with a population around 203 million people.

This technical-scientific unit of the centenarian Oswaldo Cruz Foundation (Fiocruz/MOH) plays a strategic role in the supplying of a range of pediatric vaccines for around 3 millions of newborns per year, besides biopharmaceuticals and IVD reagents, mostly for the Brazilian public health system.

Bio-Manguinhos presents high performance in the production sector, as well as in research and development aiming to create new products and technologies, know-how and economic benefits to the country.

Besides the autochthonous development with a high skilled team, the Institute has a vast experience with national and global partnerships for co-development and technological transfer processes. Currently, Bio-Manguinhos has important public-private partnerships ongoing with a view to the provision of new biotech products to the population.

Bio-Manguinhos also exports vaccines prequalified by WHO for more than 70 countries worldwide, according to United Nations Agencies request.
The Bill & Melinda Gates Foundation established a strategic alliance to prioritize the development of solutions for pressing global health issues. During the 9th Grand Challenges Meeting, the agreement between the Bill & Melinda Gates Foundation and Bio-Manguinhos was announced for the production, development and export of the vaccine protecting against rubella and measles.

The vaccines produced will be distributed in developing countries of Africa, Asia and Latin America, serviced by the Global Alliance for Vaccines and Immunization (GAVI). The expectation is 30 million doses per year to be available in the market from 2017. The initiative will rely on US$ 1.1 million of the Bill & Melinda Gates Foundation.

The vaccines produced will be distributed in developing countries of Africa, Asia and Latin America, serviced by the Global Alliance for Vaccines and Immunization (GAVI). The expectation is 30 million doses per year to be available in the market from 2017. The initiative will rely on US$ 1.1 million of the Bill & Melinda Gates Foundation.

The vaccines produced will be distributed in developing countries of Africa, Asia and Latin America, serviced by the Global Alliance for Vaccines and Immunization (GAVI). The expectation is 30 million doses per year to be available in the market from 2017. The initiative will rely on US$ 1.1 million of the Bill & Melinda Gates Foundation.

The vaccines produced will be distributed in developing countries of Africa, Asia and Latin America, serviced by the Global Alliance for Vaccines and Immunization (GAVI). The expectation is 30 million doses per year to be available in the market from 2017. The initiative will rely on US$ 1.1 million of the Bill & Melinda Gates Foundation.

The vaccines produced will be distributed in developing countries of Africa, Asia and Latin America, serviced by the Global Alliance for Vaccines and Immunization (GAVI). The expectation is 30 million doses per year to be available in the market from 2017. The initiative will rely on US$ 1.1 million of the Bill & Melinda Gates Foundation.

The vaccines produced will be distributed in developing countries of Africa, Asia and Latin America, serviced by the Global Alliance for Vaccines and Immunization (GAVI). The expectation is 30 million doses per year to be available in the market from 2017. The initiative will rely on US$ 1.1 million of the Bill & Melinda Gates Foundation.

The vaccines produced will be distributed in developing countries of Africa, Asia and Latin America, serviced by the Global Alliance for Vaccines and Immunization (GAVI). The expectation is 30 million doses per year to be available in the market from 2017. The initiative will rely on US$ 1.1 million of the Bill & Melinda Gates Foundation.